77019-8
Noninvasive prenatal fetal 18 and 21 aneuploidy panel - Plasma cell-free DNA by Sequencing
Active
77014-9 Fetal Trisomy 21 risk [Interpretation] based on Plasma cell-free DNA by Sequencing Qualitative
Term Description
This term was created for, but is not limited in use to, Sequenom Laboratories' VisibiliT Trisomy 21 test, which analyzes circulating cell-free DNA extracted from maternal plasma using whole genome sequencing to determine the risk for fetal chromosome 21 aneuploidy. VisibiliT is indicated for use in pregnant women with average risk for fetal chromosomal aneuploidy.
Source: Regenstrief LOINC
Part Descriptions
LP150045-5 Sequencing
Sequencing is a method used to determine the sequence of individual genes, larger genetic regions (i.e. clusters of genes or operons), full chromosomes or entire genomes. Historically, most sequencing has been performed using the chain termination method developed by Frederick Sanger in 1977. PMID: 271968 Sequencing technologies have improved dramatically, making them cheaper, faster, and more accurate. Next-generation sequencing (NGS), also known as high-throughput sequencing, deep sequencing, and second-generation sequencing, is a type of technology that uses parallel sequencing of multiple small fragments of DNA to determine sequence. This "high-throughput" technology has increased the speed and amount of DNA sequenced at a significantly reduced cost. PMID: 18576944 Several NGS platforms (ie, sequencing instruments and associated reagents) have been developed. Third-generation sequencing is another methodology currently under development that uses parallel sequencing similar to NGS. In contrast to NGS, third-generation sequencing uses single DNA molecules rather than amplified DNA as a template. PMID: 20858600
Source: Regenstrief LOINC
Fully-Specified Name
- Component
- Fetal trisomy 21 risk
- Property
- Imp
- Time
- Pt
- System
- Plas.cfDNA
- Scale
- Ord
- Method
- Sequencing
Additional Names
- Short Name
- Fet Ts 21 risk Plas.cfDNA Ql
- Display Name
- Trisomy 21 risk Sequencing Ql (cfDNA) [Interp]
- Consumer Name Alpha Get Info
- Fetal Trisomy 21 risk
Basic Attributes
- Class
- MOLPATH.TRISOMY
- Type
- Laboratory
- First Released
- Version 2.52
- Last Updated
- Version 2.73
- Change Reason
- Added "Fetal" to Component to clarify that the result is about the fetus.
- Order vs. Observation
- Observation
Example Answer List LL3286-3
| Answer | Code | Score | Answer ID |
|---|---|---|---|
| Low risk | LA19542-2 | ||
| High risk | LA19541-4 | ||
| Not reportable | LA22730-8 | ||
| Quantity insufficient Copyright http://snomed.info/sct ID:281268007 Insufficient sample (finding) | LA15842-0 |
Member of these Panels
| LOINC | Long Common Name |
|---|---|
| 77019-8 | Noninvasive prenatal fetal 18 and 21 aneuploidy panel - Plasma cell-free DNA by Sequencing |
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| es-ES | Spanish (Spain) | Riesgo de trisomía 21 fetal: |
| es-MX | Spanish (Mexico) | Riesgo de trisomía 21 fetal: |
| fr-FR | French (France) | Risque de trisomie 21 foetale: |
| it-IT | Italian (Italy) | Trisomia 21, rischio: Synonyms: DNA libero circolante nel plasma Impressione/interpretazione di studio Patologia molecolare Plasma Punto nel tempo (episodio) Rischio di trisomia 21 Trisomia cromosoma genetica |
| nl-NL | Dutch (Netherlands) | risico op foetale trisomie 21: Synonyms: circulerend DNA |
| zh-CN | Chinese (China) | 胎儿三体型 21 风险: Synonyms: 21 三体型综合征（唐氏综合征、 |
Third Party Copyright
This material includes SNOMED Clinical Terms® (SNOMED CT®) which is used by permission of the International Health Terminology Standards Development Organisation (IHTSDO) under license. All rights reserved. SNOMED CT® was originally created by The College of American Pathologists. "SNOMED" and "SNOMED CT" are registered trademarks of the IHTSDO.
This material includes content from the US Edition to SNOMED CT, which is developed and maintained by the U.S. National Library of Medicine and is available to authorized UMLS Metathesaurus Licensees from the UTS Downloads site at https://uts.nlm.nih.gov.
Use of SNOMED CT content is subject to the terms and conditions set forth in the SNOMED CT Affiliate License Agreement. It is the responsibility of those implementing this product to ensure they are appropriately licensed and for more information on the license, including how to register as an Affiliate Licensee, please refer to http://www.snomed.org/snomed-ct/get-snomed-ct or info@snomed.org<mailto:info@snomed.org>. This may incur a fee in SNOMED International non-Member countries.
77015-6 Fetal Trisomy 18 risk [Interpretation] based on Plasma cell-free DNA by Sequencing Qualitative
Term Description
This term was created for, but is not limited in use to, Sequenom Laboratories' VisibiliT Trisomy 18 test, which analyzes circulating cell-free DNA extracted from maternal plasma using whole genome sequencing to determine the risk for fetal chromosome 18 aneuploidy. VisibiliT is indicated for use in pregnant women with average risk for fetal chromosomal aneuploidy.
Source: Regenstrief LOINC
Part Descriptions
LP150045-5 Sequencing
Sequencing is a method used to determine the sequence of individual genes, larger genetic regions (i.e. clusters of genes or operons), full chromosomes or entire genomes. Historically, most sequencing has been performed using the chain termination method developed by Frederick Sanger in 1977. PMID: 271968 Sequencing technologies have improved dramatically, making them cheaper, faster, and more accurate. Next-generation sequencing (NGS), also known as high-throughput sequencing, deep sequencing, and second-generation sequencing, is a type of technology that uses parallel sequencing of multiple small fragments of DNA to determine sequence. This "high-throughput" technology has increased the speed and amount of DNA sequenced at a significantly reduced cost. PMID: 18576944 Several NGS platforms (ie, sequencing instruments and associated reagents) have been developed. Third-generation sequencing is another methodology currently under development that uses parallel sequencing similar to NGS. In contrast to NGS, third-generation sequencing uses single DNA molecules rather than amplified DNA as a template. PMID: 20858600
Source: Regenstrief LOINC
Fully-Specified Name
- Component
- Fetal trisomy 18 risk
- Property
- Imp
- Time
- Pt
- System
- Plas.cfDNA
- Scale
- Ord
- Method
- Sequencing
Additional Names
- Short Name
- Fet Ts 18 risk Plas.cfDNA Ql
- Display Name
- Trisomy 18 risk Sequencing Ql (cfDNA) [Interp]
- Consumer Name Alpha Get Info
- Fetal Trisomy 18 risk
Basic Attributes
- Class
- MOLPATH.TRISOMY
- Type
- Laboratory
- First Released
- Version 2.52
- Last Updated
- Version 2.73
- Change Reason
- Added "Fetal" to Component to clarify that the result is about the fetus.
- Order vs. Observation
- Observation
Example Answer List LL3286-3
| Answer | Code | Score | Answer ID |
|---|---|---|---|
| Low risk | LA19542-2 | ||
| High risk | LA19541-4 | ||
| Not reportable | LA22730-8 | ||
| Quantity insufficient Copyright http://snomed.info/sct ID:281268007 Insufficient sample (finding) | LA15842-0 |
Member of these Panels
| LOINC | Long Common Name |
|---|---|
| 77019-8 | Noninvasive prenatal fetal 18 and 21 aneuploidy panel - Plasma cell-free DNA by Sequencing |
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| es-ES | Spanish (Spain) | Riesgo de trisomía 18 fetal: |
| es-MX | Spanish (Mexico) | Riesgo de trisomía 18 fetal: |
| fr-FR | French (France) | Risque de trisomie 18 foetale: |
| it-IT | Italian (Italy) | Trisomia 18, rischio: Synonyms: DNA libero circolante nel plasma Impressione/interpretazione di studio Patologia molecolare Plasma Punto nel tempo (episodio) Rischio di trisomia 18 Trisomia cromosoma genetica |
| nl-NL | Dutch (Netherlands) | risico op foetale trisomie 18: Synonyms: circulerend DNA |
| zh-CN | Chinese (China) | 胎儿三体型 18 风险: Synonyms: 18 三体型综合征风险（危险性、 |
Third Party Copyright
This material includes SNOMED Clinical Terms® (SNOMED CT®) which is used by permission of the International Health Terminology Standards Development Organisation (IHTSDO) under license. All rights reserved. SNOMED CT® was originally created by The College of American Pathologists. "SNOMED" and "SNOMED CT" are registered trademarks of the IHTSDO.
This material includes content from the US Edition to SNOMED CT, which is developed and maintained by the U.S. National Library of Medicine and is available to authorized UMLS Metathesaurus Licensees from the UTS Downloads site at https://uts.nlm.nih.gov.
Use of SNOMED CT content is subject to the terms and conditions set forth in the SNOMED CT Affiliate License Agreement. It is the responsibility of those implementing this product to ensure they are appropriately licensed and for more information on the license, including how to register as an Affiliate Licensee, please refer to http://www.snomed.org/snomed-ct/get-snomed-ct or info@snomed.org<mailto:info@snomed.org>. This may incur a fee in SNOMED International non-Member countries.